Drugs / fluticasone furoate/vilanterol
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01627327 | Apr → Dec 2012 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fluticasone furoate/vilanterol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01627327 ↗ |
| Known as | FF/VI | “Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg” NCT01627327 ↗ |
| Route | Inhaled | “inhalation powder” NCT01627327 ↗ |